Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

PATHWAYS TO LIFE, INC

NPI: 1467695031 · GREENVILLE, NC 27858 · Counselor · NPI assigned 04/13/2009

$173K
Total Medicaid Paid
3,721
Total Claims
2,921
Beneficiaries
3
Codes Billed
2018-01
First Month
2024-09
Last Month

Provider Details

Authorized OfficialCHAPPELL, ONTARIO (PRESIDENT)
NPI Enumeration Date04/13/2009

Related Entities

Other providers sharing the same authorized official: CHAPPELL, ONTARIO

ProviderCityStateTotal Paid
PATHWAYS TO LIFE, INC GREENVILLE NC $30.43M
PATHWAYS TO LIFE, INC. NORFOLK VA $482K
PATHWAYS TO LIFE, INC RICHMOND VA $405K
PATHWAYS TO LIFE, INC. SUFFOLK VA $170K

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2018 273 $22K
2019 506 $29K
2020 200 $11K
2021 461 $20K
2022 683 $28K
2023 806 $37K
2024 792 $26K

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 3,662 2,865 $165K
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed 39 38 $4K
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed 20 18 $3K